Testing effectiveness (Phase 2)Ended earlyNCT03480152
What this trial is testing
Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
Who this might be right for
MelanomaColon CancerGastrointestinal Cancer+2 more
National Cancer Institute (NCI) 5